ClinicalTrials.gg
Active, not recruitingNCT03779854Updated Sep 25, 2026

Naive T Cell Depletion for Preventing Chronic Graft-versus-Host Disease in Children and Young Adults With Blood Cancers Undergoing Donor Stem Cell Transplant

A Phase 2 interventional study of Total-Body Irradiation and Thiotepa in Acute Biphenotypic Leukemia, Acute Leukemia and Acute Leukemia of Ambiguous Lineage, sponsored by Fred Hutchinson Cancer Center. Active, not recruiting at 9 sites in United States. Open to participants aged 6 Months to 26 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-09-25.

Sponsored by Fred Hutchinson Cancer Center · Phase 2, Interventional, and Treatment

How we know

Updated Sep 25, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
45
Allocation
Randomized
Ages
6 Months to 26 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 32 studies in Leukemia, Biphenotypic, Acute by Fred Hutchinson Cancer Center — 9 open to participants now, 12 under way, none of them phase 3. Leukemia, Biphenotypic, Acute · Fred Hutchinson Cancer Center.

Enrollment
16th of 29
45 · median 46
Started
2019
with 1 other
Phase 2
17 of 32
4 open now
Primary completion
2027-08
later than 6 of 11 live
Registered
23rd of 32
by date

Among the 32 studies in Leukemia, Biphenotypic, Acute by Fred Hutchinson Cancer Center, this one is the 16th largest by enrollment of the 29 interventional ones that give a count, is one of 2 that started in 2019, is one of 17 in phase 2, reaches primary completion later than 6 of the 11 other live ones, and was the 23rd registered.

Leukemia, Biphenotypic, Acute

246 studies on the registry are indexed under Leukemia, Biphenotypic, Acute; 53 are open to participants now.

Browse Leukemia, Biphenotypic, Acute studies →

Open to participants now

9 of the 32 studies in Leukemia, Biphenotypic, Acute by Fred Hutchinson Cancer Center are open now, in 1 country. Recruiting first, the newest first:

4 more — sign in →

By country, each count listing its studies:

All 9 open studies →

Where they have run

Who these studies take

Of the 47 Leukemia, Biphenotypic, Acute studies recruiting now, 21 (45%) set no upper age limit and 21 (45%) stop at 75 or younger; 29 take children under 18; 3 take healthy volunteers.

This study: 6 Months to 26 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 32 studies in Leukemia, Biphenotypic, Acute by Fred Hutchinson Cancer Center, or all of them as a file.
02

Study summary

This phase II trial studies how well naive T-cell depletion works in preventing chronic graft-versus-host disease in children and young adults with blood cancers undergoing donor stem cell transplant. Sometimes the transplanted white blood cells from a donor attack the body's normal tissues (called graft versus host disease). Removing a particular type of T cell (naive T cells) from the donor cells before the transplant may stop this from happening.

Read the detailed description

Patients are randomized to 1 of 2 arms. All patients receive 1 of 3 conditioning regimens.

CONDITIONING REGIMEN A: Patients undergo total body irradiation (TBI) twice daily (BID) on days -10 to -7, then receive thiotepa intravenously (IV) over 3 hours once daily (QD) on days -6 and -5, and fludarabine IV over 30 minutes once daily on days -6 to -2.

CONDITIONING REGIMEN B: Patients undergo TBI BID on days -8 to -5, then receive fludarabine IV over 30 minutes QD on days -4 to -2, and cyclophosphamide IV over 1 hour QD on days -3 and -2.

CONDITIONING REGIMEN C: Patients receive fludarabine IV over 30 minutes QD on days -6 to -2, busulfan IV over 180 minutes QD on days -5 to -2, and undergo total body irradiation BID on day -1.

ARM I: Patients receive naive T-cell depleted PBSCs on day 0.

ARM II: Patients receive unmanipulated T cell-replete BM on day 0.

GVHD PROPHYLAXIS: All patients receive tacrolimus IV on days -1 to +50 followed by a taper in the absence of grade II-IV aGVHD. Patients also receive methotrexate IV on days +1, +3, +6, and +11.

Additionally, all patients undergo echocardiography (ECHO) and cerebrospinal fluid (CSF) collection at baseline as well as blood sample collection and bone marrow aspiration with or without biopsy throughout the trial.

After completion of study treatment, patients are followed up at days 28, 56, 90, 180, 270, and 365 and then at months 15, 18, 21, and 24.

03

Conditions studied

  • Acute Biphenotypic Leukemia
  • Acute Leukemia
  • Acute Leukemia of Ambiguous Lineage
  • Acute Lymphoblastic Leukemia
  • Acute Undifferentiated Leukemia
  • Allogeneic Hematopoietic Stem Cell Transplantation Recipient
  • Blastic Plasmacytoid Dendritic Cell Neoplasm
  • Blasts Under 25 Percent of Bone Marrow Nucleated Cells
  • Blasts Under 5 Percent of Bone Marrow Nucleated Cells
  • Mixed Phenotype Acute Leukemia
  • Myelodysplastic Syndrome With Excess Blasts-1
  • Myelodysplastic Syndrome/Acute Myeloid Leukemia
  • Burkitt Leukemia
  • Chronic Monocytic Leukemia
  • Lymphoblastic Lymphoma
  • Mast Cell Leukemia
  • Myeloproliferative Neoplasm
04

Who can participate

Ages eligible
6 Months to 26 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • The patient must have one of the following diagnoses and be considered to be an appropriate candidate for HCT by the study site principal investigator (PI):

    • Acute lymphoblastic leukemia (ALL) with \< 5% marrow blasts.
    • Acute myeloid leukemia (AML) with \< 25% marrow blasts.
    • Other acute leukemia (OAL) or related neoplasm (including but not limited to acute biphenotypic leukemia [ABL], ambiguous lineage [ALAL], mixed phenotype acute leukemia [MPAL], blastic plasmacytoid dendritic cell neoplasm [BPDCN], acute undifferentiated leukemia [AUL], lymphoblastic lymphoma, Burkitt leukemia/lymphoma, mast cell leukemia, chronic monocytic leukemia [CML] with blast crisis or other chronic myeloproliferative neoplasm) with \< 5% marrow blasts.
    • Myelodysplastic syndrome (MDS) with excess blasts (EB-1 and EB-2) and has received cytotoxic induction chemotherapy (excluding small molecule inhibitors and de-methylating agents)
  • Age 6 months to 26 years at the time is obtained using the Informed Consent to Participate in a Research Study form
  • Matched related donor (MRD) or matched unrelated donor (MUD) (defined as 8/8 match for human leukocyte antigen [HLA]-A, -B, -C, -DRB1).
  • Planned product type for infusion is PBSC or BM (i.e. not cord blood):

    • For feasibility phase, planned product type for infusion must be PBSC.
    • For RCT, planned product type must be PBSC or BM.
  • or Lansky score >= 60%.
  • (LVEF) at rest >= 40%.
  • Diffusing capacity of the lungs for carbon monoxide (DLCO) (corrected for ) >= 60% predicted by pulmonary function tests (PFTs)

    * Patients who are unable to perform PFTs (age \< 6 years or considered developmentally incapable of PFTs): oxygen saturation (by oximetry) must be >= 92% on room air.

  • Total =\< 2 x (ULN) (unless value[s] > 2 x ULN are disease- or medication-related).

    * If value(s) are > 2 x ULN and not disease- or medication related, patient must be evaluated by a gastrointestinal (GI) physician. If GI physician considers protocol treatment to be for the patient, the patient will not be eligible for the study.

  • (ALT), aspartate aminotransferase (AST) =\< 2 x ULN (unless value[s] > 2 x ULN are disease- or medication-related).

    * If value(s) are > 2 x ULN and not disease- or medication related, patient must be evaluated by a gastrointestinal GI physician. If GI physician considers protocol treatment to be contraindicated for the patient, the patient will not be eligible for the study.

  • Serum creatinine (SCr) within normal range for age. If SCr is outside normal range for age, (CrCl) > 40 mL/min/1.73m\^2 must be obtained (measured by 24-hour [hr] urine specimen or nuclear [GFR]).

    • Age (Years): Maximum SCr (mg/dL)
    • =\< 5: 0.8
    • 6-10: 1
    • 11-15: 1.2
    • > 15: 1.5
  • Recipient informed consent/assent/legal guardian permission documentation must be obtained.
  • DONOR: May be related (MRD) or unrelated (MUD) to the subject.
  • DONOR: Must be matched to the subject at 8/8 HLA alleles (HLA-A, -B, -C, and -DRB1)
  • DONOR: Be >=14 years of age.
  • DONOR: Must be available to donate in the United States of America (USA) (i.e. excludes international donors).
  • DONOR: Must agree to donate BM or PBSC (i.e. agree to donate whichever product type is requested) (applicable only to the RCT phase of this study).
  • DONOR: MUDs:

    • Must give informed consent according to applicable National Marrow Donor Program (NMDP) donor regulatory requirements
    • Must meet eligibility criteria as defined by the NMDP or be ineligible with statement of urgent medical need (exception 21 CFR 1271.65(b)(iii))

      • Tests must be performed using Food and Drug Administration (FDA) licensed, cleared, and approved test kits in a Clinical Laboratory Improvement Amendments (CLIA)-certified laboratory
  • DONOR: MRDs:

    • Must be negative for (HIV)-1, HIV-2, human T-lymphotropic virus (HTLV)-1, HTLV-2, , (serological and/or nucleic acid testing [NAT] and/or other approved testing)
    • Must meet institutional donor eligibility criteria, or be ineligible with statement that the donor is a first or second degree relative (exception 21 CRF 1271.65(b)(i)).

      • Tests must be performed using FDA licensed, cleared, and approved test kits in a CLIA-certified laboratory.

Exclusion criteria

Exclusion Criteria:

  • Active central nervous system (CNS) disease. A patient may have a history of CNS disease; however, any CNS disease must be cleared by the end of the pre-conditioning evaluation. If CNS disease is identified on the first cerebrospinal fluid (CSF) evaluation within 30 days of the start of the preparative regimen, a repeat CSF evaluation must be performed and show no evidence of disease in order for the patient to be eligible for the protocol.
  • Patients on other experimental protocols for the prevention of .
  • Patient body weight:

    • Matched related donor (MRD): > 100 kg are ineligible
    • Matched unrelated donor (MUD): > 75 kg must be discussed with the protocol principal investigator (PI) prior to enrollment.
  • -positive.
  • Uncontrolled infections must be evaluated by an infectious disease physician and considered suitable to undergo HCT by the study site PI, infectious disease physician and protocol PI. Upper respiratory tract infection (URI) does not constitute an uncontrolled infection in this context.
  • \< 3 months from disease other than acute leukemia or myelodysplastic syndrome (MDS).
  • Significant medical condition that would make recipient unsuitable for HCT.
  • Prior or autologous HCT.
  • Females who are pregnant or breastfeeding.
  • Patients of child bearing age who are presumed to be fertile and are unwilling to use an effective method or refrain from sexual intercourse during study treatment and for 12 months following HCT.
  • Known to tacrolimus, fludarabine, or methotrexate (MTX).
Terms in these criteria, in plain language(18)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

GVHD (graft-versus-host disease)

After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
45 participants (actual)

Study arms

  • Experimental
    Arm I (chemotherapy, naive T-cell depleted PBSC)

    CONDITIONING REGIMEN A: Patients undergo TBI BID on days -10 to -7, then receive thiotepa IV over 3 hours QD on days -6 and -5, and fludarabine IV over 30 minutes once daily on days -6 to -2. CONDITIONING REGIMEN B: Patients undergo TBI BID on days -8 to -5, then receive fludarabine IV over 30 minutes QD on days -4 to -2, and cyclophosphamide IV over 1 hour QD on days -3 and -2. CONDITIONING REGIMEN C: Patients receive fludarabine IV over 30 minutes QD on days -6 to -2, busulfan IV over 180 minutes QD on days -5 to -2, and undergo total body irradiation BID on day -1. TRANSPLANT: Patients receive naive T-cell depleted PBSCs on day 0. GVHD PROPHYLAXIS: All patients receive tacrolimus IV beginning on day -1 and methotrexate IV on days 1, 3, 6, and 11. Additionally, patients undergo ECHO and CSF collection at baseline as well as blood sample collection and bone marrow aspiration with or without biopsy throughout the trial.

    Radiation: Total-Body Irradiation · Drug: Thiotepa · Drug: Fludarabine · Drug: Cyclophosphamide · Drug: Busulfan · Drug: Tacrolimus · Drug: Methotrexate · Procedure: Naive T Cell-Depleted Hematopoietic Stem Cell Transplantation · Procedure: Echocardiography · Procedure: Biospecimen Collection · Procedure: Bone Marrow Aspiration · Procedure: Bone Marrow Biopsy

  • Active comparator
    Arm II (chemotherapy, unmanipulated T cell replete BM)

    CONDITIONING REGIMEN A: Patients undergo TBI BID on days -10 to -7, then receive thiotepa IV over 3 hours QD on days -6 and -5, and fludarabine IV over 30 minutes once daily on days -6 to -2. CONDITIONING REGIMEN B: Patients undergo TBI BID on days -8 to -5, then receive fludarabine IV over 30 minutes QD on days -4 to -2, and cyclophosphamide IV over 1 hour QD on days -3 and -2. CONDITIONING REGIMEN C: Patients receive fludarabine IV over 30 minutes QD on days -6 to -2, busulfan IV over 180 minutes QD on days -5 to -2, and undergo total body irradiation BID on day -1. TRANSPLANT: Patients receive unmanipulated T cell-replete BM on day 0. GVHD PROPHYLAXIS: All patients receive tacrolimus IV beginning on day -1 and methotrexate IV on days 1, 3, 6, and 11. Additionally, patients undergo ECHO and CSF collection at baseline as well as blood sample collection and bone marrow aspiration with or without biopsy throughout the trial.

    Radiation: Total-Body Irradiation · Drug: Thiotepa · Drug: Fludarabine · Drug: Cyclophosphamide · Drug: Busulfan · Procedure: Allogeneic Bone Marrow Transplantation · Drug: Tacrolimus · Drug: Methotrexate · Procedure: Echocardiography · Procedure: Biospecimen Collection · Procedure: Bone Marrow Aspiration · Procedure: Bone Marrow Biopsy

Interventions

  • RadiationTotal-Body Irradiation

    Undergo TBI

    Also known as: Total Body Irradiation, Whole-Body Irradiation, SCT_TBI, TBI, Whole Body Irradiation

  • Given IV

    Also known as: 1,1',1"-phosphinothioylidynetrisaziridine, Oncotiotepa, STEPA, Tepadina, Tespamin, Tespamine, Thio-Tepa, Thiofosfamide, Thiofozil, Thiophosphamide, Thiophosphoramide, triethylenethiophosphoramide

  • Given IV

    Also known as: 2-Fluoro-9-beta-arabinofuranosyladenine, 2-Fluorovidarabine, Fluradosa

  • Given IV

    Also known as: Carloxan, Ciclofosfamida, Ciclofosfamide, Cicloxal, Clafen, Claphene, Cycloblastin, Cytophosphane

  • Given IV

    Also known as: Bussulfam, Busulfanum, Busulfex, Busulphan, Misulban, Misulfan, Mitosan, Myeleukon

  • ProcedureAllogeneic Bone Marrow Transplantation

    Receive unmanipulated T cell replete BM

    Also known as: Allo BMT, Allogeneic Blood and Marrow Transplantation, Allogeneic BMT

  • Given IV

    Also known as: Fujimycin, Hecoria, Prograf, Protopic

  • Given IV

    Also known as: Abitrexate, Alpha-Methopterin, Amethopterin, Brimexate, Emtexate, Emthexat, Emthexate, Farmitrexat, Medsatrexate, Methoblastin, Rheumatrex

  • ProcedureNaive T Cell-Depleted Hematopoietic Stem Cell Transplantation

    Receive naive T-cell depleted PBSCs

  • ProcedureEchocardiography

    Undergo ECHO

    Also known as: EC, ECHO

  • ProcedureBiospecimen Collection

    Undergo CSF and blood sample collection

  • ProcedureBone Marrow Aspiration

    Undergo bone marrow aspiration

  • ProcedureBone Marrow Biopsy

    Undergo bone marrow biopsy

06

What researchers measure

Primary outcomes

  1. Feasibility achievement

    Success defined as achievement of cell selection goals for two consecutive Naive T cells (TN)-depleted peripheral blood stem cells (PBSC) hematopoietic cell transplantation (HCTs) at each study site (Feasibility)

    Time frame: Up to 2 years

  2. Engraftment of neutrophils by day 28 (Feasibility)

    Success defined as achievement neutrophil engraftment (absolute neutrophil count \[ANC\] \>= 500/mm\^3) on first day of three consecutive laboratory values obtained on different days.

    Time frame: At day 28

  3. Current-graft versus host disease (GVHD)-free, relapse-free survival (Randomized Controlled Trial [RCT])

    Defined as alive, no relapse after HCT, no current GVHD requiring prednisone, no graft rejection or graft failure. The proportion of subjects meeting the primary endpoint will be described in each arm with 90% confidence intervals (CI) and compared between arms using the chi-square test. A two-sided 10% significance level will be used for this comparison.

    Time frame: At 1 year

Secondary outcomes

  1. Chronic GVHD (cGVHD) meeting National Institutes of Health (NIH) criteria and requiring prednisone (RCT)

    Cumulative incidence curve will be computed for each arm along with a 90% CI at 1 year and 2 years post-HCT. Death and/or relapse prior to occurrence of cGVHD will be considered as competing risks. The cumulative incidence curves will be compared between arms using Gray's test. The maximum severity of cGVHD will also be described in each arm and compared using the chi-squared test.

    Time frame: At 1 and 2 years

  2. Proportion of subjects alive and off prednisone (or equivalent systemic corticosteroid) for treatment of GVHD (RCT)

    Proportions of subjects alive without requiring use of prednisone (or equivalent systemic corticosteroid) for GVHD will be estimated with 90% CI for both arms at time points over 24 months, and compared using the chi-squared test.

    Time frame: At 3, 6, 9, 12, 15, 18, 21 and 24 months post HCT

07

Study locations

9 sites
08

References and documents

Publications

  • Bleakley M. Naive T-cell depletion in stem cell transplantation. Blood Adv. 2020 Oct 13;4(19):4980. doi: 10.1182/bloodadvances.2020001888. PubMed 33049057 ↗

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2019 (actual). Primary completion is estimated for Aug 2027, 96 months after the start.

Of 42 phase 2 interventional studies under Leukemia, Biphenotypic, Acute, half reached primary completion within 102 months of starting (the median), counting those still running; a quarter within 47 and three quarters within 153. This study's planned 96 months is close to that.

Since we started tracking on Sep 25, 2026, the dates moved once, on Sep 25, 2026: primary completion Dec 2028 → Aug 2027 and completion Dec 2028 → Aug 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Dec 17, 2018
First posted
Dec 19, 2018
StartActual
Aug 29, 2019
Primary completionEst.
Aug 31, 2027was Dec 2028
CompletionEst.
Aug 31, 2027was Dec 2028
Last update
Sep 25, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Dec 31, 2028→Aug 31, 2027
Sep 25, 2026
Study completion
Dec 31, 2028→Aug 31, 2027
Sep 25, 2026
Show all 1 update
  1. Sep 25, 2026
    Primary completion Dec 31, 2028→Aug 31, 2027
    Study completion Dec 31, 2028→Aug 31, 2027
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT03779854
Responsible party
Sponsor
First posted
Dec 19, 2018
Start date
Aug 29, 2019
Primary completion
Aug 31, 2027 (estimated)
Completion
Aug 31, 2027 (estimated)
Last update
Sep 25, 2026

Study contacts

Marie Bleakley
principal investigator · Fred Hutch/University of Washington Cancer Consortium

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion